Health Canada approves Pfizer’s Eraxis for fungal infections
Pfizer said that Eraxis has been shown to be an effective new agent in the treatment of invasive candidiasis in a Phase III trial involving 47 trial sites
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.